Mauna Kea Technologies

Mauna Kea Technologies' mission is to transform medical decision-making by providing real-time cellular visualization during diagnostic and therapeutic procedures. Its flagship Cellvizio® platform, a confocal laser endomicroscopy system, has achieved significant commercial traction with over 100,000 patient procedures, 1,300+ clinical publications, and more than 20 FDA clearances. The company's strategy focuses on expanding indications, integrating AI, and leveraging strategic partnerships with players like Johnson & Johnson and Telix Pharmaceuticals to drive global adoption and penetrate new markets.

The Cellvizio® platform is a probe-based Confocal Laser Endomicroscopy (CLE) system that provides real-time, in vivo cellular imaging during endoscopic and surgical procedures, enabling 'optical biopsy' through ultra-thin, disposable miniprobes.